CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for StageZero Life Sciences Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

StageZero Life Sciences Ltd
30-70 East Beaver Creek Road
Phone: (905) 209-2030p:905 209-2030 RICHMOND HILL, ON  L4B 3B2  Canada Ticker: GEN GEN
Business Summary
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2022Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2835 In vitro and in vivo diagnostic substances
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer James R.Howard-Tripp 1/1/2020 1/1/2002
Chief Financial Officer, Chief Operating Officer MatthewPietras 8/28/2021 8/28/2021
Independent Director Harry A.Glorikian 57 4/1/2008 4/1/2008
Independent Director Garth A.Macrae 86 1/1/2000 1/1/2000
Independent Director Rory B.Riggs 70 7/15/2013 1/1/2000

Subsidiaries
Business Name Address City State/Province Country
Innovative Diagnostic Laboratory, LLP 8751 Park Central Drive, Suite 200 Richmond VA United States

Business Names
Business Name
61N1
CDG
ChondroGene Limited
7 additional Business Names available in full report.

General Information
Number of Employees: 40 (As of 12/31/2022)
Outstanding Shares: 123,532,948 (As of 6/30/2024)
Stock Exchange: TSE
Fax Number: (905) 209-2030


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024